Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 Seattle, WA; Cambridge, MA; Tokyo, Japan – 18 October – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from […]
DefEYE, Inc. and Lovell Government Services Announce Partnership to IncreaseAccess to the Biovance Product Portfolio for VA/DoD Health Affairs
PENSACOLA, Florida — October 9, 2025 – Lovell® Government Services (Lovell) and DefEYE,Inc. (DefEYE), an exclusive provider of BIOVANCE® decellularized basement membranes forocular use, announced today that they have partnered to serve federal healthcare systemsincluding the Veterans Health Administration, the Department of Defense Military HealthSystem, and the Indian Health Service. Lovell will serve as DefEYE’s […]
EyeDura Initiates Preclinical Efficacy Studies to Advance Insulin-Based Treatment for Neurotrophic Keratitis
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a leader in preservative-free, topical sustained-release ophthalmic therapies, today announced initiating preclinical efficacy studies with the Singapore Eye Research Institute (SERI) towards continued development of its lead insulin-based topical eye drop treatment for neurotrophic keratitis (NK), a rare eye disease affecting approximately 71,000 patients in the U.S. “This partnership […]
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
Strategic appointments fuel global clinical and commercial development of AURN001, a transformational cell therapy with the potential to restore vision Seattle, WA; Cambridge, MA; Tokyo, Japan – 30 September – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced the promotions of Andrew Torres, Ph.D., to Chief […]
EyeDura Initiates Preclinical Efficacy Studies to Advance Insulin-Based Treatment for Neurotrophic Keratitis
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a leader in preservative-free, topical sustained-release ophthalmic therapies, today announced initiating preclinical efficacy studies with the Singapore Eye Research Institute (SERI) towards continued development of its lead insulin-based topical eye drop treatment for neurotrophic keratitis (NK), a rare eye disease affecting approximately 71,000 patients in the U.S. “This partnership […]
DefEYE Inc. Launches as Independent Ophthalmics-Focused Company Delivering Innovative Decellularized Human Placenta-Derived Biologics for Eye Care
Emerging from Verséa Health and Backed by Industry Veterans, DefEYE, Inc. setsits sights on enhancing clinical and surgical care across ocular conditions SARASOTA, FL., October 1, 2025 — DefEYE Inc. (DefEYE), a privately held ophthalmic biologicscompany with a portfolio of decellularized biologic solutions, today announced its launch as anindependent company, effective October 1, 2025. The […]
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
Strategic appointments fuel global clinical and commercial development of AURN001, a transformational cell therapy with the potential to restore vision Seattle, WA; Cambridge, MA; Tokyo, Japan – 30 September – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced the promotions of Andrew Torres, Ph.D., to Chief […]
Visionary Clients Driving the Future of Eye Care
At LaunchLab Partners, we are proud to support companies that are redefining what’s possible in ophthalmology. The Visionary Breakthroughs supplement in Cataract & Refractive Surgery Today and Glaucoma Today recently spotlighted three of our clients for their groundbreaking innovations: Amaros is transforming ophthalmology with precision intelligence. Their technology unifies fragmented clinical and research data into […]
EYEDURA’S SUSTAINED-RELEASE EYE DROP TECHNOLOGY WINS DOUBLE INDUSTRY HONORS
Sustained-released platform has the potential to deliver therapeutic levels for seven days and beyond, addressing key treatment challenges in eye care NEW YORK — July 15, 2025 — (Business Wire) EyeDura Therapeutics Inc. (www.eyedura.com), a developer of preservative-free sustained release ophthalmic therapies, announced that it received top recognition at two major industry forums among a […]
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Inc. (www.amaros.ai), a leader in ophthalmic intelligence and the developer of AI-powered EvidenceEngine platform, today announced the successful close of its Series A financing. Backed by a select group of new and existing mission-aligned investors, the round validates Amaros’ mission to transform fragmented clinical data into real-time, actionable intelligence for eye care. […]
